Risk adjusted net present value: What is the current valuation of Adicet Bio’s ADI-001?
ADI-001 is a gene-modified cell therapy commercialized by Adicet Bio, with a leading Phase I program in Lupus Nephritis.
ADI-001 is a gene-modified cell therapy commercialized by Adicet Bio, with a leading Phase I program in Lupus Nephritis.
What's Your Reaction?
